- Home
- ALLY vs QGEN Comparison
ALLY vs QGEN Comparison
Compare ALLY & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLY | QGEN |
|---|---|---|
| Founded | 1919 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.2B |
| IPO Year | 2011 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ALLY | QGEN |
|---|---|---|
| Price | $42.92 | $37.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $54.42 | $45.76 |
| AVG Volume (30 Days) | ★ 2.9M | 2.1M |
| Earning Date | 04-17-2026 | 05-06-2026 |
| Dividend Yield | 2.74% | ★ 7.17% |
| EPS Growth | ★ 31.67 | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $7,914,000,000.00 | N/A |
| Revenue This Year | $24.30 | $8.18 |
| Revenue Next Year | $4.31 | $5.71 |
| P/E Ratio | $45.03 | ★ $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.91 | $32.53 |
| 52 Week High | $47.27 | $57.82 |
Technical Indicators
Market Signals| Indicator | ALLY | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 56.26 |
| Support Level | $40.19 | $32.85 |
| Resistance Level | $43.54 | $38.10 |
| Average True Range (ATR) | 0.95 | 0.88 |
| MACD | 0.02 | 0.33 |
| Stochastic Oscillator | 60.27 | 78.03 |
Price Performance
Historical ComparisonAbout ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).